No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMIX Autonomix Medical
- 1.120
- -0.230-17.04%
Close Jun 18 16:00 ET
- 1.070
- -0.050-4.46%
Post 18:24 ET
21.11MMarket Cap-1367P/E (TTM)
1.455High0.940Low2.13MVolume1.380Open1.350Pre Close2.76MTurnover24.60%Turnover RatioLossP/E (Static)18.85MShares7.60052wk High2.77P/B9.68MFloat Cap0.94052wk Low--Dividend TTM8.64MShs Float7.600Historical High--Div YieldTTM38.15%Amplitude0.940Historical Low1.301Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersSonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 63.8% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. As per the news, the Q4 earnings rep
Express News | Autonomix Medical: Responder Patients Reported Mean 78% Improvement in Quality of Health at 7 Days Post-Procedure
Express News | Autonomix Medical: 60% Of Study Subjects Responded With Mean 6.33 Reduction of Pain on Vas Pain Scale at 7 Days Post-Procedure
Express News | Autonomix Medical Inc: Trial Remains on Track to Complete Enrollment by Year-End 2024
Express News | Autonomix Announces Positive Topline Results From First Five Lead-in Patients in Ongoing Human Clinical Trial
Comments
$Autonomix Medical(AMIX.US$ SS’s are a viscous bunch! hehehe! Average price here is about 3.15+- hehehe
2
$Autonomix Medical(AMIX.US$ Reuters· 1 min ago
Autonomix Announces Positive Topline Results From First Five Lead-in Patients in Ongoing Human Clinical Trial
Autonomix Announces Positive Topline Results From First Five Lead-in Patients in Ongoing Human Clinical Trial
1
$Autonomix Medical(AMIX.US$ Autonomix to Announce Preliminary Topline Results From First Five Lead-in Patients in Ongoing Human Clinical Trial on June 18, 2024
Autonomix Medical To Release Preliminary Results From Proof-Of-Concept Trial For Pancreatic Cancer Pain Treatment On June 18, 2024
Autonomix Medical To Release Preliminary Results From Proof-Of-Concept Trial For Pancreatic Cancer Pain Treatment On June 18, 2024
$Autonomix Medical(AMIX.US$
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical (NASDAQ: AMIX) announced the approval of a protocol amendment by the Ethics Committee for its ongoing proof-of-concept human clinical trial. The trial evaluates the safety and efficacy of delivering transvascular energy to ablate nerves and mitigate pain in pancreatic cancer patients. Following the treatm...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical (NASDAQ: AMIX) announced the approval of a protocol amendment by the Ethics Committee for its ongoing proof-of-concept human clinical trial. The trial evaluates the safety and efficacy of delivering transvascular energy to ablate nerves and mitigate pain in pancreatic cancer patients. Following the treatm...
1
$Autonomix Medical(AMIX.US$
NEWS
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
Autonomix Medical announced the successful completion of a preclinical animal study demonstrating that targeted nerve ablation can significantly reduce tumor mass growth and metastases in pancreatic cancer. The study, involving mice injected with human pancreatic tumor cells, showed a 60% reduction in local invasion and a 40% decrease in liver...
NEWS
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
Autonomix Medical announced the successful completion of a preclinical animal study demonstrating that targeted nerve ablation can significantly reduce tumor mass growth and metastases in pancreatic cancer. The study, involving mice injected with human pancreatic tumor cells, showed a 60% reduction in local invasion and a 40% decrease in liver...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
